Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Susanne Saußele

Porträt Dr Saußele 2016 KopieProfessor Susanne Saußele, MD

Head, CML Excellence Center

III. Medizinische Klinik, Hematology and Oncology
University of Mannheim

Mannheim, Germany

 

Susanne Saußele studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. She completed her thesis in the laboratory of Prof Dr Hehlmann and made her habilitation in Internal Medicine in 2013. In 2017, she was appointed as Professor of the University of Heidelberg. Currently, she is the leader of the CML Excellence Center in Mannheim including the molecular laboratory and the Study Centre of the German CML Study Group. She is acting as chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg. Prof Saußele is also active as a project leader in EUTOS (European treatment and Outcome Study of CML) and in the E-MPN network (European network for MPN)and as active member in the ELN CML Working Party. Additionally she is member of the Scientific Program Committee of EHA.

Languages spoken: German, English

 

Qian Jiang

 

Qian JiangProfessor Qian JIANG, M.D.

Professor of International Medicine

Peking University People’s Hospital

Peking University Institute of Hematology

China

 

Medical education

  • 1984-1990: M.D. Peking University Health Science Center

Clinical history

  • 2017 - present: Chief Physician and Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
  • 2010 - 2017: Chief Physician and Associate Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
  • 2004 - 2010: Associate Chief Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
  • 1996 - 2004: Attending Doctor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
  • 1990 - 1996: Resident Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology

Research interests

  • Clinical research of CML, MPN, AML, ALL, and CLL

 

 

 

Carolina Pavlovsky

Dr Carolina Pavlovsky, MDCarolina Pavlovsky

Fundaleu Hospital and Clinical Research Center

Buenos Aires, Argentina

 

Carolina Pavlovsky works as a hematologist at Fundaleu (Foundation to fight Leukemia) in Buenos Aires and serves as Head of the Research Department since 2010. She received her doctorate from the University of Buenos Aires and completed her training in internal medicine and hematology at the National Academy of Medicine in Buenos Aires.


Her main interests are chronic leukemias: molecular and clinical aspects. Since 2003, she has worked on multiple research protocols for chronic leukemias and is in charge of CML and CLL projects. Since 2005, she has coordinated an Argentine multi-center study on molecular monitoring in patients with CML and since 2011 she coordinates the clinical aspects of a new multi-centric study on mutational analysis of patients with CML and treatment failure. In June 2008, she undertook a training at the Department of Leukemias at the MD Anderson Cancer Center in Houston. In 2014 she obtained a Master's degree in Molecular Oncology from the National Cancer Research Center of Spain (CNIO) and the European School of Oncology (ESO).

Ricardo Teixeira

Ricardo Teixeira Fernandes, M.D.

Executive Director of the OncoHemato Clinic

Rio de Janeiro, BrazilFoto - Dr. Ricardo Teixeira


Dr. Ricardo Teixeira is the Executive Director of the OncoHemato Clinic in Rio de Janeiro (Brazil). He specialized in medical oncology and clinical hematology according to the guidelines of the Brazilian Medical Association. He graduated in medicine at the School of Medicine at the Fluminense Federal University in Niterói in the State of Rio de Janeiro and made his residency at the Lagoa hospital in Rio de Janeiro. He undertook a visitorship at the M.D. Anderson Cancer Center and John Hopkins Hospital in the USA. He is fellow of the Oncological Institute of the Gregorio Marañón Hospital of the Complutensis University and Master in Palliative Medicine (Madrid Autonoma University in Madrid, Spain). Dr Teixeira used to be chief of the Clinic of Medical Oncology and Clinical Hematology in the São Paulo Air Hospital and Chief at the Bonsucesso General Hospital in Rio de Janeiro.

Dr. Teixeira has published many articles on various subjects in clinical hematology and medical oncology in important international periodics. His last publication was the official publication of the Mexican Hematology Society about CML. He participated in the first clinical trial with Mitoxantrone in Brazil.

Dr. Texeira has recently undertaken a 4-weeks preceptorship at the Leukemia Department in M.D. Anderson Cancer Center (University of Texas). He will disseminate the preceptorship program of the iCMLf in Brazil in order to offer this training to young hematologists. 

Profile_Francisco Cervantes

Francisco Cervantes, MD, PhDPhoto Cervantes 1

Hematology Department

Hospital Clínic

University of Barcelona

Barcelona, Spain

 

Dr Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic of Barcelona and professor at the University of Barcelona. His scientific interest has been focused on the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published over 300 articles in peer-review journals. He was coauthor of the publications of the IRIS study that allowed the approval of imatinib as frontline treatment of CML, participated in the introduction of the second-generation tyrosine kinase inhibitors, and is a member of the expert panels of the European LeukemiaNet for CML and MPN treatment. In the MPN field, he was the leading author of the prognostic classification of primary myelofibrosis or IPSS. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for MPN Research and Treatment, the European LeukemiaNet, and the PETHEMA Spanish Collaborative Group.

 

Nicolas Novitzky

Professor Nicolas Novitzky, FCP(SA), PhD

Prof. Novitzky

Department of Haematology

University of Cape Town, South Africa



ACADEMIC AND PROFESSIONAL QUALIFICATIONS:

  • Diploma in Medicine, La Plata University, Buenos Aires, Argentina (December 1974).
  • Residency in Internal Medicine (3 year course).  Teodoro Alvarez Teaching Hospital belonging to the University of Buenos Aires (May 1975 – April 1978).
  • Postgraduate Fellowship in Clinical Haematology, Haematology Section, Hospital Clinico, Catholic University, Santiago, Chile (August 1978 – November 1978).
  • Postgraduate Fellowship in Clinical and Laboratory Haematology, Groote Schuur Hospital/University of Cape Town, South Africa (January 1979 – January 1982).
  • Registrar in Internal Medicine, Groote Schuur Hospital/University of Cape Town, South Africa (February 1982 – July 1983).
  • Fellow of the College of Physicians of South Africa FCP(SA) (College of Medicine) – May 1984.
  • Educational Commission for Foreign Medical Graduates Certificate (ECFMG).  Visa Qualifying Examination (VQE), United States of America – January 1989.
  • Certification (Sub-specialty) in Clinical Haematology (College of Medicine) – 1998.
  • Specialist in Internal Medicine (Master in Medicine – MMed) - May 1993.
  • Philosophy Doctor in Medicine (PhD), University of Cape Town, South Africa - June 1994.

RESEARCH OUTPUTS:

Professor Novitzky has contributed to chapters in books and 89 research publications in local and international peer-reviewed and educational journals.  He has been a Principle Investigator for over 25 clinical trials relating to Chronic Myelogenous Leukaemia (CML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Non-Hodgkin’s Lymphoma, etc.

His main areas of interest include haematopoietic stem cell transplantation, immune reconstitution following immune depleting therapies, stem cell biology and clonal malignant disorders.

 

Profile_Andrzej Hellmann

Andrzej Hellmann MD, PhDProf. Andrejz Hellmann
Head of the Department of Hematology

University of Gdańsk, Poland

Andrzej Hellmann is Professor of Medicine and head of the Department of Hematology of Medical University of Gdańsk since 1991. He received his medical degree in 1971 and PhD in 1976 from Medical University of Gdańsk.
Dr Hellmann completed a postdoctoral fellowship in leukemia biology at the Hammersmith Hospital in London in 1978 – 80. He is a specialist in internal medicine, hematology and clinical transplantology.  From 1982 to 1990 he was associate professor at Department of Medicine. In 1991 he organized and was appointed head of the new established Department of Hematology with BMT Unit at University of Gdańsk. Prof. Hellmann is author and co- author of more than 300 peer–reviewed articles in medical journals including NEJM and Blood. During a period 2005 – 2008 Prof. Hellmann was acting as a vice – rector of Medical University of Gdańsk. From   2003 till 2011Prof. Hellmann was the president of the Polish Society of Hematology and Transfusion Medicine. He is also the chairman of CML Study Group within the Polish Adult Leukemia Group. He is also the member of European Leukemia Network, American Society of Hematology, European Hematology Association, European Group for Blood and Marrow Transplantation, and International Society of Hematology. His special practical and research interest is still focused on myeloproliferative neoplasms.

             

 

 

Profile_Peter Valent

Professor Peter Valent, MDFOTO VALENT

Senior Researcher and Senior Clinician 
Medical University of Vienna, Austria 

 

Professor Dr. Peter Valent is M.D. and a Senior Researcher as well as Senior Clinician at the Medical University of Vienna, Austria. He is the Scientific Director of the Ludwig Boltzmann Cluster Oncology (LB-CO) and leads a Special Research Program on Myeloproliferative Neoplasms in his University. He also coordinates a Clinical Study Group working in the field of myeloid neoplasms (focusing on CML, MDS, AML and mastocytosis) and is head of the Outpatient Clinics and Hematology Ambulatory in his institution. Professor Valent also participates in several other Research Programs in Vienna, including one dedicated to Cardiovascular Biology (10 years) and one dedicated to Allergic Diseases (20 years). Professor Valent is coordinator of the Vienna Cancer Stem Cell Club (VCSCC), coordinator of an International Working Group on Eosinophil Disorders (ICOG-EO), and coordinator of the European Competence Network on Mastocytosis (ECNM). He also coordinates the CML-Platform and MDS-Platform of the Austrian Society for Hematology and Oncology (ÖGHO), runs a Center of Excellence of the MDS Foundation, a Center of Excellence and Reference Center of the ECNM, and a Reference Center in CML. During the past 15 years, Professor Valent has organized a number of scientific meetings in Vienna, including several Consensus Conferences on Diagnostic Criteria and Diagnostic Standards. A special focus in his research are neoplastic stem cells; the identification of novel markers and targets in myeloid neoplasms; the development of disease-related criteria and targeted drug therapies in myeloid neoplasms; and the evaluation of target interaction profiles and side effects of novel drugs. Professor Valent is member in diverse Medical Societies, including the American Society of Hematology (ASH), and serves on various editorial boards and as a reviewer in most top hematology journals. He published more than 500 peer-reviewed articles and numerous review articles in his areas of expertise, lectured widely in Europe, North America, and Japan, and received numerous scientific awards. His h index arrived at 74, first-author h index at 32, and total citations at >21,000.

 

 

Profile_Francois-Xavier Mahon

 

Professor Francois-Xavier Mahon

Professor and Senior House Physician

University of Bordeaux, FranceDr Mahon

 

Professor Mahon gratuated in clinical hematology from the faculty of medicine, University of Bordeaux and received a PhD for his work on "Selection of Normal Cells in Chronic Myeloid Leukaemia". Professor Mahon has completed a Research Fellowship at the Imperial College in London (UK) and is a felllow of the American Society of Hematology (ASH), the European Hematology Association (EHA), the French Society of Hematology, and the European Investigators on CML Group (El-CML). He currently serves as the President of the French Group of CML (Fl-LMC) and today has authored or co-authored for than 160 articles in peer-reviewed journals.